A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

Cancer

Volumn 121, Issue 19, 2015, Pages 3465-3471

  Fenske, Timothy S ^a   Shah, Namrata M ^a   Kim, Kyung Mann ^b   Saha, Sandeep ^b   Zhang, Chong ^b   Baim, Arielle E ^a   Farnen, John P ^c   Onitilo, Adedayo A ^d   Blank, Jules H ^e   Ahuja, Harish ^f   Wassenaar, Tim ^g   Qamar, Rubina ^h   Mansky, Patrick ⁱ   Traynor, Anne M ^b   Mattison, Ryan J ^b   Kahl, Brad S ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^d MARSHFIELD CLINIC   (United States)

^e St Vincent Regional Cancer Center CCOP   (United States)

^f Aspirus Cancer Center   (United States)

^g ProHealth Care Regional Cancer Center   (United States)

^h Aurora Cancer Care   (United States)

ⁱ Bellin Health   (United States)

Author keywords

bortezomib; clinical trial; non Hodgkin lymphoma; phase 2; temsirolimus

Indexed keywords

BORTEZOMIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; RAPAMYCIN;

AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; HUMAN; HYPERLIPIDEMIA; INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; INCIDENCE; LYMPHOMA, NON-HODGKIN; MORTALITY; WISCONSIN;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; SIROLIMUS; WISCONSIN;

EID: 84941940489     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29502     Document Type: Article

References (25)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Crawford LJ, Irvine AE,. Targeting the ubiquitin proteasome system in haematological malignancies. Blood Rev. 2013; 27: 297-304.
3. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al., Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002; 20: 4420-4427.
4. Goy A, Younes A, McLaughlin P, et al., Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 667-675.
5. Di Bella N, Taetle R, Kolibaba K, et al., Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010; 115: 475-480.
6. O'Connor OA, Moskowitz C, Portlock C, et al., Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol. 2009; 145: 34-39.
7. O'Connor OA, Wright J, Moskowitz C, et al., Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005; 23: 676-684.
8. Fisher RI, Bernstein SH, Kahl BS, et al., Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006; 24: 4867-4874.
9. Blachly JS, Baiocchi RA,. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol. 2014; 167: 19-32.
10. Witzig TE, Geyer SM, Ghobrial I, et al., Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005; 23: 5347-5356.
11. Ansell SM, Inwards DJ, Rowland KM Jr, et al., Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008; 113: 508-514.
12. Hess G, Herbrecht R, Romaguera J, et al., Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009; 27: 3822-3829.
13. Smith SM, van Besien K, Karrison T, et al., Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago Phase II Consortium. J Clin Oncol. 2010; 28: 4740-4746.
14. Wright JJ,. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res. 2010; 16: 4094-4104.
15. Ghobrial IM, Weller E, Vij R, et al., Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011; 12: 263-272.
16. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published May 29, 2009; Updated 2009. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed April 13, 2014.
17. Simon R,. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
18. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
19. Zhang J, Grubor V, Love CL, et al., Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013; 110: 1398-1403.
20. Cristobal I, Manso R, Rincon R, et al., Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells. J Cancer Res Clin Oncol. 2014; 140: 1249-1250.
21. Yang Y, Chen Y, Saha MN, et al., Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia. 2015; 29: 715-726.
22. Michallet M, Sobh M, El-Cheikh J, et al., Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. Exp Hematol. 2013; 41: 1008-1015.
23. Al-Homsi AS, Cole K, Bogema M, Duffner U, Williams S, Mageed A,. Short course of post-transplantation cyclophosphamide and bortezomib for graft-versus-host disease prevention after allogeneic peripheral blood stem cell transplantation is feasible and yields favorable results: a phase I study [published online ahead of print March 9, 2015 ]. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2015.02.008.
24. Wang M, Popplewell LL, Collins RH Jr, et al., Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014; 165: 510-518.
25. Conconi A, Raderer M, Franceschetti S, et al., Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. Br J Haematol. 2014; 166: 69-76.